IQVIA (NYSE:IQV) Rating Lowered to “Hold” at StockNews.com

IQVIA (NYSE:IQV) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other equities analysts also recently weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. UBS Group increased their price objective on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $259.13.

IQVIA Stock Up 0.7 %

Shares of IQVIA stock opened at $219.23 on Friday. IQVIA has a 52-week low of $190.20 and a 52-week high of $261.73. The stock has a 50-day simple moving average of $231.00 and a 200-day simple moving average of $229.31. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a market cap of $39.79 billion, a price-to-earnings ratio of 28.77, a P/E/G ratio of 2.26 and a beta of 1.51.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IQVIA

Large investors have recently modified their holdings of the business. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter valued at about $27,000. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter worth $28,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA during the 2nd quarter worth $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.